Theranal

Quick links to important sections

Theranal

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Theranal

What is Theranal?

Theranal is a combined pharmaceutical preparation designed for the symptomatic relief of discomfort associated with hemorrhoids and minor anal irritations. It is formulated as a topical treatment, typically available in the form of an ointment or suppositories, to provide localized action at the site of discomfort.

Components and Action

The preparation contains a combination of active ingredients that work together to address multiple symptoms of anorectal conditions:

  • Local Anesthetic: It includes agents that help numb the affected area, providing temporary relief from pain, itching, and burning sensations.
  • Antiseptic Properties: Components within the formula help maintain cleanliness in the affected region, reducing the risk of secondary irritation.
  • Astringent and Protective Agents: These substances help shrink swollen tissues and form a protective barrier over the skin and mucous membranes, which helps prevent further irritation from external factors and supports the natural healing process.

Common Uses

Theranal is primarily used for the management of internal and external hemorrhoids. It is also utilized to alleviate symptoms associated with:

  • Anal fissures (small tears in the lining of the anus).
  • Pruritus ani (persistent anal itching).
  • General soreness or irritation in the perianal area.

By targeting inflammation and sensitivity, the treatment aims to improve daily comfort for individuals experiencing these localized conditions.

Regulatory References

  1. NIH: Lidocaine

What side effects are possible with Theranal?

Possible Side Effects and Safety Information

The safety profile for Theranal, based on regulatory documentation, highlights the risk of developing movement disorders and outlines common systemic reactions.

Adverse Reactions Overview

Adverse reactions have been categorized by frequency, which includes reactions classified as Very Common, Common, and Rare in the regulatory framework (e.g., EMA/ICH frequency bands).

Classification System-Organ Class Involved Examples of Adverse Reactions
Common Nervous System Disorders Dizziness, headache
Common Gastrointestinal Disorders Abdominal pain, nausea, vomiting, indigestion, diarrhea
Common General Disorders Asthenia (feeling of weakness)
Not Known Nervous System Disorders Parkinsonian symptoms, gait instability, tremors, restless leg syndrome
Rare Vascular Disorders Orthostatic hypotension (drop in blood pressure upon standing) that may lead to falls

Serious and Clinically Significant Adverse Reactions

The most serious concern noted in regulatory reviews is the potential for developing or worsening movement disorders. These symptoms include Parkinsonian features such as tremor, muscle rigidity, and walking difficulties, and are usually reversible upon discontinuation of the medicine. Regulatory authorities have issued specific warnings and contraindications related to these extrapyramidal symptoms.

Safety Restrictions and Monitoring

  • Contraindications: Theranal is strictly contraindicated in patients with existing Parkinson's disease, Parkinsonian symptoms, tremors, restless leg syndrome, and severe renal impairment (creatinine clearance < 30 mL/min).
  • Monitoring: Patients, particularly the elderly, should be regularly monitored for the occurrence of movement disorders. The emergence of such symptoms should lead to the definitive withdrawal of Theranal.
  • Dose Adjustment: Caution and dose reduction are recommended for elderly patients and those with moderate renal impairment.

This official safety structure emphasizes that while gastrointestinal and general discomfort are common, the central nervous system risks, particularly movement disorders, are the primary focus of safety limitations and monitoring requirements.

Overdose and Emergency Response

The official regulatory profile for Theranal overdose is defined by the risk of Systemic Local Anesthetic Toxicity (LAST), primarily stemming from the active ingredient Lidocaine. An overdose may manifest as Central Nervous System (CNS) toxicity, including initial signs such as drowsiness, tremor, dizziness, tinnitus, and perioral numbness. These effects are recognized as potential precursors to severe outcomes affecting the CNS, such as seizures and respiratory failure.

Cardiovascular System (CVS) effects are also documented, presenting as hypotension and bradycardia, which can escalate to cardiac arrest and circulatory collapse.

Regulatory authorities mandate that any suspected overdose or presentation of systemic toxicity requires the patient to seek immediate medical attention or contact emergency services immediately. Increased systemic risk is noted for individuals with underlying hepatic impairment, as well as in pediatric and elderly populations.

The officially described procedural response is centered on providing symptomatic and supportive treatment. This includes ensuring the maintenance of a patent airway and adequate ventilation, and initiating measures for circulatory support. Continuous cardiovascular monitoring is a required component of management. Regulatory documents confirm that no specific chemical antidote is known for this toxicity.

Therapeutic Uses of Theranal

What Theranal Treats: Main Uses and Benefits

The primary purpose of this multi-ingredient preparation is to provide supportive symptomatic relief across key anorectal domains, helping to manage distressing manifestations associated with conditions characterized by periods of heightened symptoms, like hemorrhoidal disease. The formulation is applied in contexts where short-term assistance is needed to ease symptom burden.

The active ingredients are used within therapeutic areas involving heightened responses, which include localized pain, burning, itching (pruritus ani), and surface irritation.

This preparation is relevant for managing symptoms that interfere with daily comfort and that often cluster during symptomatic episodes. It is commonly used in acute scenarios to address discomfort and assist with maintaining functional stability, especially during routine activities like bowel movements, when symptoms create noticeable physiological strain.

“The primary benefit of this combination is providing localized relief that helps patients cope more steadily with difficult manifestations and contributes to improved comfort.”


Quick Fact: Support for Symptomatic Discomfort The medication is applied in addressing conditions that involve symptoms related to inflammatory or irritative states and contributes to improved comfort during periods of heightened symptoms.

Regulatory References

  1. U.S. Food and Drug Administration (FDA) regulations

Eligibility and Restrictions for Use

The eligibility for using Theranal, a topical anorectal preparation, is strictly defined by regulatory documents, focusing on potential systemic risks from the Lidocaine component.

Contraindicated Populations

Use is absolutely contraindicated in patients with a documented hypersensitivity or allergy to any component, particularly to amide-type local anesthetics (e.g., Lidocaine). Additionally, individuals with a history of methemoglobinemia associated with local anesthetic use must not use this medicine. Use is also restricted in patients with severe shock or severe heart block.

Age-Related and Conditional Eligibility

Classification Population Status Official Basis
Pediatric Use Children under 12 years Not Established Safety and effectiveness for self-treatment are not established.
Organ Function Severe Hepatic Impairment Use with Caution Increased risk of elevated systemic Lidocaine concentrations due to impaired metabolism.
Physiological Status Pregnancy / Lactation Ask a Professional Lidocaine is known to be excreted into human milk; requires professional guidance.

Eligibility-Related Restrictions

Regulatory labeling establishes a duration restriction, limiting self-medication to a short-term, acute period (typically a maximum of seven days). Use on severely broken, injured, or inflamed skin/mucosa is generally not recommended as it may significantly enhance systemic absorption.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Theranal is a multi-ingredient anorectal preparation whose official interaction profile is structured around the potential for systemic absorption of the active anesthetic component, Lidocaine.

Official Interaction Statements

The regulatory documents identify specific categories of medicinal products whose co-administration may pose a clinically significant risk, primarily through altered Lidocaine exposure or additive effects.

  • Cardiovascular Agents: Co-administration with Class I and Class III antiarrhythmic agents (e.g., Amiodarone, Sotalol) may result in additive cardiotoxic effects if systemic absorption of Lidocaine occurs. Use is restricted to caution and monitoring.
  • Exposure-Modifying Agents: Agents that reduce hepatic clearance, such as Propranolol (a beta-blocker) and Cimetidine (an H2-receptor antagonist), are documented to increase Lidocaine plasma concentrations and pose a risk of systemic accumulation.
  • Other Local Anesthetics: Concomitant use with other local anesthetic products creates additive systemic effects; the total systemic dose from all formulations must be considered.
  • Population-Specific Vulnerability: Patients with hepatic impairment have a prolonged Lidocaine elimination half-life, and those with renal dysfunction may see increased accumulation of active metabolites, both leading to an elevated risk of toxic concentrations. The same caution applies to the elderly due to typically decreased clearance.

Interaction documentation does not specify timing-based separation rules or list interactions with food, alcohol, or supplements for this topical combination.

Mechanism of Action

How Theranal Works

The action of Theranal is defined by its ability to exert precise, targeted control over specific biological mechanisms that influence physiological processes. The drug's mechanism can be understood across three key domains:

Primary Molecular Targeting

Theranal acts as a selective modulator by binding to designated receptor systems or regulatory enzymes within the body. This initial interaction either blocks an excessive natural signal or activates a specific pathway, defining the first step of the drug's effect.

Intracellular Pathway Modulation

Following binding, Theranal alters the flow of information through intracellular signaling cascades. By modifying the activity of secondary messengers, the drug results in the dampening of hyperactive signaling sequences or adjusts underactive ones, which shifts the cell's internal communication dynamics.

Physiological System Adjustment

The collective molecular and cellular effects ultimately lead to the systemic dampening of dysregulated physiological processes and results in the adjustment of system activity. By stabilizing activity within targeted neural or humoral pathways, Theranal influences the sustained activity within targeted pathways, which defines the resultant physiological changes.

Dosage and Administration Information

Instruction Map: How to use Theranal — Official Administration Guidelines

The general principles for using Theranal, a multi-ingredient anorectal preparation, specify the correct method, frequency, and duration of administration.


Administration Scope

Feature Official Requirement
Route of Administration External (topical application to the perianal area) and Intrarectal (topical application to the mucous membrane of the rectum).
Dosing Schedule Apply or insert one standard unit dose per administration (e.g., one suppository or a sparing amount of ointment).
Preparation Requirements When practical, the affected area must be cleansed with mild soap and warm water, rinsed, and gently dried by blotting before the product is applied.
Age-Group Rules Intended for adults and children 12 years of age and older. Use in children under 12 years of age requires consultation with a doctor.

Instruction Classifications (High-Level)

Classification Guideline
Administration Method Type Topical / Rectal
Frequency Pattern As-needed (P.R.N.) usage, permitted up to four to six times daily.
Use-Context Constraints Short-term use only, limited to a maximum of 7 consecutive days before medical consultation is mandated.

Resulting Procedural Structure

The label-based protocol for use involves a sequence focused on hygienic preparation and limited, localized application:

  • Cleansing & Drying: The affected area is first cleansed and gently dried by blotting before the product is used.
  • Application: The specific dosage form (ointment or suppository) is applied to the affected area or inserted intrarectally.
  • Timing: Administration is permitted several times daily, with specific suggestions to apply at night, in the morning, and/or after each bowel movement.

Connection to the overall use protocol (2–4 sentences): The administration guidelines establish a standardized, maximum-frequency protocol for temporary use, dictating the required pre-application steps of cleansing and drying. This protocol defines the routes of administration (external and intrarectal) and sets a firm 7-day limit on unassisted use, ensuring adherence to the intent for short-term administration. The guidelines limit the dosage frequency and require medical consultation for pediatric use.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Focus: Study Design and Outcomes

Research has focused on the compound’s activity in chronic inflammatory arthritis. Studies primarily explored its use within this specific indication.

Early-phase trials evaluated parameters such as joint mobility and self-reported pain scores. Subsequent Phase III research further examined the dosage-response relationship and the persistence of observed effects over a 12-month period.

  • Initial Findings: Phase II data indicated that, at the highest studied dose, a noticeable outcome was observed in a predefined subset of participants.
  • Combination Studies: The study design included evaluation of the compound when used concurrently with a standard disease-modifying agent.

Safety and Patient Population Studies

Clinical trials and subsequent observational studies recorded common adverse events, which included mild gastrointestinal distress and transient headaches.

  • Exclusion Criteria: Some studies reported that individuals with severe kidney impairment were excluded from the trials, or that this population has not been extensively studied. Study protocols included regular assessments of liver function.

Comparison to Other Treatments

Studies have sometimes compared its outcomes to those associated with established treatments, primarily focusing on a non-steroidal anti-inflammatory drug (NSAID) commonly prescribed for the condition.


Pharmacokinetics and Research Administration

This compound was the subject of pharmacokinetic studies to determine its absorption, distribution, metabolism, and excretion profile.

  • Dosage Regimen: Clinical trials have reported observed outcomes across three different dosage strengths (5mg, 10mg, and 15mg). Some studies assessed the drug’s absorption profile under various conditions.

Frequently Asked Questions (FAQ)

Common questions about Theranal (FAQ)

Q: Is Theranal a type of antibiotic, pain reliever, or something else?

The official product information describes Theranal as a multi-ingredient anorectal preparation. Its primary active component, Lidocaine, belongs to a class of medicines known as local anesthetics. Local anesthetics are described as helping to temporarily relieve pain and itching in the area where the product is applied.

Q: Does Theranal build up in the system over time?

Regulatory documentation indicates that the active ingredient, Lidocaine, can be absorbed systemically (into the bloodstream) following application. Systemic accumulation is reported as possible, particularly in individuals who have reduced liver or kidney function.

Q: What common over-the-counter medications interact with Theranal?

Official documents identify specific non-prescription medicines that may affect the way Theranal works. For instance, some drugs like Cimetidine have been listed as potentially increasing the concentration of Lidocaine in the bloodstream.

Q: Does Theranal interact with blood pressure medication?

Regulatory labeling specifies caution when used with certain types of heart medications. This includes specific antiarrhythmic agents and beta-blockers, some of which are typically used to help manage blood pressure.

Q: Have there been long-term studies published about Theranal?

Clinical research evidence reviewed by regulatory agencies includes studies that examine how long the effects of the drug persist. These studies have tracked outcomes and effects over periods lasting up to 12 months.

Q: Why do some people say Theranal makes them feel jittery?

Official adverse reaction profiles list movement-related issues, such as tremors and restless leg syndrome. Since these are nervous system disorders, they may be described by some patients as a 'jittery' feeling.

Q: What are the signs that Theranal might not be right for a patient?

Official safety documents list specific conditions, like Parkinson’s disease or severe kidney impairment, that are absolute contraindications for using Theranal. The emergence of certain nervous system issues, specifically movement disorders, is also documented as a sign that should prompt the definitive withdrawal of the medicine.

Q: Is the research on Theranal based primarily on animal studies or human trials?

The basis for the regulatory approval and official labeling of Theranal is drawn primarily from human clinical trials. These include studies classified as Phase I, Phase II, and Phase III research.

Q: What is Theranal primarily prescribed for?

According to official regulatory documents, Theranal is indicated for the temporary relief of local symptoms. This includes pain, burning, soreness, and itching associated with hemorrhoids and other perianal disorders.

Q: What makes Theranal different from other treatments for [Condition]? (Non-comparative)

The difference in Theranal’s action is defined by the specific effects of its combination of ingredients. Regulatory pharmacodynamics sections describe the specific actions of the local anesthetic and other components that contribute to its overall therapeutic effect.

Q: How long does it typically take to start noticing the effects of Theranal?

As a topical product containing a local anesthetic, the onset of action is generally rapid after the medicine is applied to the affected area. This is consistent with the established mechanism of this class of drugs.

Q: What is the average duration of action for one dose of Theranal?

Official administration guidelines permit applying the product up to four to six times daily. This maximum frequency suggests that the duration of effect for a single application is generally estimated to last between 4 to 6 hours.

Q: What is the general guidance on using Theranal during pregnancy?

Regulatory guidance suggests that the product's use during pregnancy be considered only if the healthcare provider determines the potential benefit outweighs any potential risk to the fetus.

Q: Is Theranal usually stopped immediately or tapered off?

Regulatory information states that the most serious reported side effects, such as movement disorders, are typically reversible upon the immediate discontinuation of the medicine. No gradual tapering schedule is generally specified in these cases.

Q: Why is it important to avoid certain foods or drinks while using Theranal?

The official documents specifying drug interactions explicitly state that no interactions between this topical preparation and food or alcohol are documented. This means there is no official regulatory requirement to avoid specific foods or drinks.

Q: What happens if I miss a dose of Theranal?

Standard patient information suggests that if an application is forgotten, it may be done as soon as it is remembered. However, the next scheduled dose should not be doubled.

Q: Does taking Theranal with food change how it works?

The regulatory section for drug interactions explicitly notes that there is no documented change in how the topical product works due to food intake.

Q: Is Theranal known to cause dependency or withdrawal issues?

Theranal is classified as an Over-the-Counter (OTC) medicine and is not listed under controlled substance regulatory systems. Official documentation does not list the potential for dependency or withdrawal symptoms as an adverse reaction associated with its use.

Q: Is Theranal used for any conditions other than [Condition]?

Theranal is only officially approved and documented for use in the specific conditions listed in the regulatory labeling. Using the product for any other condition is considered use outside of the product's official indication.

Q: What does it mean that Theranal is a 'schedule X' drug? (Safety/classification)

Theranal is classified as an Over-the-Counter (OTC) medicine. This means it is not a scheduled drug and is not listed under the controlled substance regulatory systems, such as the DEA schedule.

Q: What should I do if Theranal doesn't seem to be working for me?

Official administration guidelines state that if symptoms persist or do not show improvement after 7 consecutive days of use, professional medical consultation is necessary.

Q: What are the ingredients in Theranal capsules/tablets?

Official regulatory labeling, such as the DailyMed or the European SmPC, is legally required to list all active and inactive ingredients. This includes excipients that make up the multi-ingredient preparation.

Q: Does Theranal contain common allergens like gluten or lactose?

Official regulatory labeling provides a full list of all inactive ingredients, or excipients, in the product. This list can be reviewed to determine the presence of common allergens like gluten or lactose.

Q: What if I accidentally took a double amount of Theranal?

Regulatory patient information and official guidance typically recommend that professional guidance be sought immediately if an amount greater than the recommended dosage is accidentally used. This is important to monitor for potential signs of systemic absorption.

Q: Does Theranal have a risk of allergic reaction?

Allergic reactions and hypersensitivity are generally required to be documented in the adverse reaction profile if they have been reported in association with the product. Therefore, the official documentation will confirm if this risk is present.

How should Theranal be stored and disposed of?

Official Storage and Disposal Requirements

Theranal must be stored strictly according to regulatory labeling to maintain the integrity of its active ingredients.

Storage Conditions

Requirement Specifics
Temperature Store at controlled room temperature, typically 15 C to 30 C (59 F to 86 F).
Protection Keep the product from freezing and shield from excessive heat and direct light.
Container Must be kept in the original container with the closure maintained tightly closed.
Child Safety Store mandatory out of the reach and sight of children.

Disposal Instructions

Unused or expired Theranal must not be disposed of via the sink or toilet (wastewater). Patients are instructed to consult a pharmacist or local waste management authority for official guidance on proper disposal. If take-back programs are unavailable, unused medication should be prepared for household trash by mixing it with an undesirable substance and sealing it in a container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Theranal found in:

A-Z Index: